Trial reportAnnals of the American Thoracic Society2026
Quetiapine modestly improves sleep and breathing but impairs next-day performance in people with obstructive sleep apnea and difficulty maintaining sleep: a randomized controlled trial.
Trial report in Annals of the American Thoracic Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05303935 (Effects of Quetiapine on Sleep and Next Day Alertness in People With Obstructive Sleep Apnea), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effects of Quetiapine on Sleep and Next Day Alertness in People With Obstructive Sleep Apnea
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
Abstract
rationaleQuetiapine is commonly prescribed "off-label" to people with insomnia symptoms. People with undiagnosed obstructive sleep apnea (OSA) frequently report insomnia symptoms, particularly difficulty maintaining sleep. In 2023, 10.7 million prescriptions were dispensed for quetiapine in the United States. Yet, there is limited information regarding the effects of quetiapine on sleep, breathing, and next-day performance in people with OSA.
objectivesTo determine the effects of 50 mg of quetiapine versus placebo on OSA severity and other polysomnographic parameters plus next-day vigilance and driving simulator performance in people with OSA who also reported difficulty maintaining sleep.
methodsWe performed a double-blind, randomized, placebo-controlled, cross-over study (NCT05303935) in 15 people with OSA and difficulty maintaining sleep. Participants were studied overnight via polysomnography twice approximately 1 week apart and received either 50 mg of quetiapine or placebo (order randomized) just prior to sleep. A 10-minute psychomotor vigilance task (PVT) and 30-minute driving simulator test were performed each morning.
resultsCompared to placebo, quetiapine reduced the apnea/hypopnea index (primary outcome) (mean ± SD: 27 ± 16 vs 20 ± 12 events/hour, P = .009), arousal index (32 ± 16 vs 25 ± 9 arousals/hour, P = .012), and increased sleep efficiency (80 ± 11 vs 87 ± 9%, P <.001) without worsening hypoxemia (mean overnight oxygen saturation: 94.7 ± 1.2% vs 94.5 ± 1.5%, P = .38). However, next-morning vigilance (median PVT reaction time: 336 ± 48 vs 382 ± 84 ms, P = .008) and driving simulator performance (steering deviation: 72 ± 38 vs 96 ± 53 cm, P <.01) were significantly impaired with quetiapine.
conclusionsConsistent with a hypnotic effect, a single night of low-dose quetiapine reduced OSA severity as measured via the apnea/hypopnea index and increased sleep efficiency without worsening overnight hypoxemia. However, there was evidence of next-day impairment in vigilance and driving simulator performance. CLINICAL
trial registrationNCT05303935.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.